Buckhead Capital Management LLC lifted its stake in Charles River Laboratories International, Inc. (NYSE:CRL – Free Report) by 9.3% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 20,089 shares of the medical research company’s stock after acquiring an additional 1,703 shares during the quarter. Buckhead Capital Management LLC’s holdings in Charles River Laboratories International were worth $4,054,000 as of its most recent filing with the Securities and Exchange Commission.
Other institutional investors and hedge funds have also recently bought and sold shares of the company. Nomura Asset Management Co. Ltd. boosted its holdings in Charles River Laboratories International by 7.5% in the first quarter. Nomura Asset Management Co. Ltd. now owns 12,846 shares of the medical research company’s stock worth $2,593,000 after purchasing an additional 895 shares in the last quarter. Nicholas Company Inc. lifted its holdings in Charles River Laboratories International by 20.7% in the 1st quarter. Nicholas Company Inc. now owns 59,986 shares of the medical research company’s stock worth $12,106,000 after purchasing an additional 10,275 shares during the last quarter. Brown Brothers Harriman & Co. grew its holdings in Charles River Laboratories International by 92.6% during the first quarter. Brown Brothers Harriman & Co. now owns 9,592 shares of the medical research company’s stock valued at $1,936,000 after purchasing an additional 4,611 shares during the last quarter. FMR LLC raised its position in shares of Charles River Laboratories International by 32.6% in the first quarter. FMR LLC now owns 739,009 shares of the medical research company’s stock valued at $149,147,000 after purchasing an additional 181,803 shares during the period. Finally, ExodusPoint Capital Management LP boosted its holdings in shares of Charles River Laboratories International by 668.5% during the 1st quarter. ExodusPoint Capital Management LP now owns 60,090 shares of the medical research company’s stock worth $12,127,000 after buying an additional 52,271 shares during the period. Hedge funds and other institutional investors own 98.91% of the company’s stock.
Insider Transactions at Charles River Laboratories International
In related news, CAO Michael Gunnar Knell sold 1,471 shares of the firm’s stock in a transaction on Thursday, August 10th. The shares were sold at an average price of $216.54, for a total transaction of $318,530.34. Following the completion of the transaction, the chief accounting officer now directly owns 9,940 shares of the company’s stock, valued at $2,152,407.60. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In related news, CAO Michael Gunnar Knell sold 1,471 shares of the stock in a transaction dated Thursday, August 10th. The shares were sold at an average price of $216.54, for a total value of $318,530.34. Following the sale, the chief accounting officer now directly owns 9,940 shares of the company’s stock, valued at approximately $2,152,407.60. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Joseph W. Laplume sold 700 shares of the stock in a transaction dated Thursday, August 10th. The stock was sold at an average price of $216.52, for a total transaction of $151,564.00. Following the transaction, the executive vice president now owns 24,983 shares in the company, valued at $5,409,319.16. The disclosure for this sale can be found here. Insiders have sold 7,934 shares of company stock worth $1,722,048 in the last quarter. Company insiders own 1.30% of the company’s stock.
Charles River Laboratories International Stock Performance
Shares of Charles River Laboratories International stock traded down $2.14 on Monday, reaching $198.25. 208,907 shares of the company traded hands, compared to its average volume of 523,882. The company has a debt-to-equity ratio of 0.82, a current ratio of 1.49 and a quick ratio of 1.21. Charles River Laboratories International, Inc. has a 52 week low of $181.22 and a 52 week high of $262.00. The firm has a market capitalization of $10.16 billion, a PE ratio of 21.41, a PEG ratio of 1.80 and a beta of 1.33. The company has a 50 day moving average of $207.08 and a 200 day moving average of $206.61.
Charles River Laboratories International (NYSE:CRL – Get Free Report) last announced its earnings results on Wednesday, August 9th. The medical research company reported $2.69 earnings per share for the quarter, beating analysts’ consensus estimates of $2.63 by $0.06. Charles River Laboratories International had a net margin of 11.58% and a return on equity of 18.99%. The firm had revenue of $1.06 billion for the quarter, compared to analyst estimates of $1.05 billion. During the same quarter in the previous year, the firm posted $2.77 EPS. The company’s revenue for the quarter was up 8.9% compared to the same quarter last year. Equities analysts forecast that Charles River Laboratories International, Inc. will post 10.48 earnings per share for the current year.
Analyst Upgrades and Downgrades
CRL has been the topic of several recent analyst reports. StockNews.com raised shares of Charles River Laboratories International from a “hold” rating to a “buy” rating in a research note on Friday. Bank of America upped their price target on shares of Charles River Laboratories International from $235.00 to $245.00 and gave the company a “buy” rating in a report on Thursday, August 10th. Citigroup cut Charles River Laboratories International from a “buy” rating to a “neutral” rating and cut their target price for the company from $260.00 to $225.00 in a research note on Monday, July 10th. JPMorgan Chase & Co. boosted their price objective on shares of Charles River Laboratories International from $225.00 to $250.00 and gave the stock an “overweight” rating in a research report on Thursday, August 10th. Finally, Credit Suisse Group lowered their price target on shares of Charles River Laboratories International from $260.00 to $255.00 in a research note on Friday, May 12th. Three investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $247.80.
About Charles River Laboratories International
Charles River Laboratories International, Inc, a non-clinical contract research organization, provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).